This study is the first to evaluate circulating OPG and TRAIL and outcomes following a breast cancer diagnosis in a large cohort of breast cancer patients with postdiagnosis blood samples (n = 2,456; largest prior study in breast cancer patients, n = 504). Here, TNFRSF11B is linked to breast cancer.